A Phase I/IIa, Randomized Double Blind, Placebo-Controlled, Dose Escalating Study to Evaluate the Safety and Tolerability of Topically Applied Bisphosphocin Nu-3 on Infected Diabetic Ulcers of Subjects With Type I or II Diabetes Mellitus

Trial Profile

A Phase I/IIa, Randomized Double Blind, Placebo-Controlled, Dose Escalating Study to Evaluate the Safety and Tolerability of Topically Applied Bisphosphocin Nu-3 on Infected Diabetic Ulcers of Subjects With Type I or II Diabetes Mellitus

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Apr 2017

At a glance

  • Drugs Nu 3 (Primary)
  • Indications Diabetic foot ulcer
  • Focus Adverse reactions
  • Sponsors Lakewood Amedex
  • Most Recent Events

    • 04 Apr 2017 According to a Lakewood Amedex media release, top-line data from the study is anticipated in the second quarter 2017.
    • 10 Mar 2017 Study design has been changed from three cohort to five cohort. Also elderly patients are also enrolled in the trial.
    • 10 Mar 2017 Planned number of patients changed from 30 to 50.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top